Last reviewed · How we verify

NCT05222126

Efficacy of Ultrasound-Guided Hydrodissection in Carpal Tunnel Syndrome

Completed NA Last updated 11 January 2024
What this trial tests

NA trial testing Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose in Musculoskeletal Diseases in 80 participants. Completed in 10 January 2024.

Timeline
20 September 2022
Primary endpoint
20 December 2023
10 January 2024

Quick facts

Lead sponsorAfyonkarahisar Health Sciences University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment80
Start date20 September 2022
Primary completion20 December 2023
Estimated completion10 January 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Afyonkarahisar Health Sciences University

Who can join

Adults 20 to 60, any sex, with Musculoskeletal Diseases or Median Nerve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of our study is to determine the effectiveness of US-guided hydrodissection of the median nerve in different contents and volumes in patients diagnosed with mild to moderate carpal tunnel syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Musculoskeletal Diseases

Currently open trials in the same condition.

Other Afyonkarahisar Health Sciences University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing